{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:35:13Z","timestamp":1791293713676,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T00:00:00Z","timestamp":1682985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","primary-care-diabetes.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Primary Care Diabetes"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.pcd.2023.04.010","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T17:13:02Z","timestamp":1683047582000},"page":"379-385","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Response to insulin glargine 100\u00a0U\/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-na\u00efve participants from nine randomised clinical trials"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-7164","authenticated-orcid":false,"given":"Wolfgang","family":"Landgraf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Bigot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Frier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geremia B.","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcd.2023.04.010_bib1","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1007\/s00125-015-3722-5","article-title":"The new biology of diabetes","volume":"58","author":"Pajvani","year":"2015","journal-title":"Diabetologia"},{"issue":"9922","key":"10.1016\/j.pcd.2023.04.010_bib2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(13)62219-9","article-title":"The many faces of diabetes: a disease with increasing heterogeneity","volume":"383","author":"Tuomi","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pcd.2023.04.010_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/1573399811666150416122903","article-title":"Heterogeneity of pre-diabetes and type 2 diabetes: implications for prediction, prevention, and treatment responsiveness","volume":"12","author":"Faerch","year":"2016","journal-title":"Curr. Diabetes Rev."},{"key":"10.1016\/j.pcd.2023.04.010_bib4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6","key":"10.1016\/j.pcd.2023.04.010_bib5","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S2213-8587(19)30087-7","article-title":"Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data","volume":"7","author":"Dennis","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.pcd.2023.04.010_bib6","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S2213-8587(19)30187-1","article-title":"Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study","volume":"7","author":"Zaharia","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.pcd.2023.04.010_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S2213-8587(18)30316-4","article-title":"Novel subgroups of patients with adult-onset diabetes in Chinese and US populations","volume":"7","author":"Zou","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.pcd.2023.04.010_bib8","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1007\/s00125-021-05625-x","article-title":"A novel diabetes typology: towards precision diabetology from pathogenesis to treatment","volume":"65","author":"Herder","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2023.04.010_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabres.2018.05.014","article-title":"Stratification of type 2 diabetes based on routine clinical markers","volume":"141","author":"Safai","year":"2018","journal-title":"Diabetes Res Clin. Pract."},{"issue":"9","key":"10.1016\/j.pcd.2023.04.010_bib10","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1007\/s00125-021-05490-8","article-title":"Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study","volume":"64","author":"Slieker","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pcd.2023.04.010_bib11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00125-021-05543-y","article-title":"Subgroups of patients with young-onset type 2 diabetes in India reveal insulin deficiency as a major driver","volume":"65","author":"Prasad","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.pcd.2023.04.010_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.637945","article-title":"Novel reclassification of adult diabetes is useful to distinguish stages of b-cell function linked to the risk of vascular complications: the DOLCE study from Northern Ukraine","volume":"12","author":"Fedotkina","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.pcd.2023.04.010_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s00125-021-05567-4","article-title":"Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial","volume":"65","author":"Pigeyre","year":"2022","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.pcd.2023.04.010_bib14","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/dom.14063","article-title":"Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN\u20106 cardiovascular outcomes trials","volume":"22","author":"Kahkoska","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.pcd.2023.04.010_bib15","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2337\/dc20-2806","article-title":"Cluster analysis of cardiovascular phenotypes in patients with type 2 diabetes and established atherosclerotic cardiovascular disease: a potential approach to precision medicine","volume":"45","author":"Sharma","year":"2022","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pcd.2023.04.010_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259372","article-title":"Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial)","volume":"16","author":"Aoki","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.pcd.2023.04.010_bib17","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1111\/dom.14767","article-title":"T2DM subgroups and response to glucose-lowering therapy: results from EDICT and Qatar study","volume":"24","author":"Abdul-Ghani","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"2","key":"10.1016\/j.pcd.2023.04.010_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/dom.13528","article-title":"The association of basal insulin treatment versus standard care with outcomes in anti-GAD positive and negative subjects: a post-hoc analysis of the ORIGIN trial","volume":"21","author":"Birkeland","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.pcd.2023.04.010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110012","article-title":"Distribution and characteristics of newly-defined subgroups of type 2 diabetes in randomised clinical trials: post hoc cluster assignment analysis of over 12,000 study participants","volume":"190","author":"Landgraf","year":"2022","journal-title":"Diabetes Res Clin. Pract."},{"issue":"3","key":"10.1016\/j.pcd.2023.04.010_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/dom.13897","article-title":"Fasting C\u2010peptide, a biomarker for hypoglycaemia risk in insulin\u2010na\u00efve people with type 2 diabetes initiating basal insulin glargine 100 U\/mL","volume":"22","author":"Landgraf","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"12","key":"10.1016\/j.pcd.2023.04.010_bib21","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","article-title":"Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes: a randomized, controlled trial","volume":"138","author":"Fritsche","year":"2003","journal-title":"Ann. Intern Med."},{"key":"10.1016\/j.pcd.2023.04.010_bib22","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The Treat-to-Target Trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Riddle","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2023.04.010_bib23","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1055\/s-2006-925222","article-title":"Once\u2212daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility","volume":"38","author":"Standl","year":"2006","journal-title":"Horm. Metab. Res"},{"key":"10.1016\/j.pcd.2023.04.010_bib24","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","article-title":"Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride","volume":"37","author":"Eliaschewitz","year":"2006","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.pcd.2023.04.010_bib25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","article-title":"Triple therapy in type 2 diabetes. Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-na\u00efve patients","volume":"9","author":"Rosenstock","year":"2006","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.pcd.2023.04.010_bib26","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jdiacomp.2015.05.022","article-title":"Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy","volume":"29","author":"Hollander","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.pcd.2023.04.010_bib27","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2023.04.010_bib28","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0140-6736(08)60485-7","article-title":"Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial","volume":"371","author":"Bretzel","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pcd.2023.04.010_bib29","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","article-title":"24-Week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs","volume":"33","author":"Swinnen","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2023.04.010_bib30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/dc16-2215","article-title":"Glucose concentrations of less than 3.0 mmol\/L (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"40","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pcd.2023.04.010_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109067","article-title":"Novel strategies for glycaemic control and preventing diabetic complications applying the clustering-based classification of adult- onset diabetes mellitus: a perspective","volume":"180","author":"Tanabe","year":"2021","journal-title":"Diabetes Res Clin. Pract."},{"key":"10.1016\/j.pcd.2023.04.010_bib32","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1038\/s41467-022-34754-z","article-title":"Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population","volume":"13","author":"Zaghlool","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pcd.2023.04.010_bib33","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"}],"container-title":["Primary Care Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991823000931?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1751991823000931?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:02:03Z","timestamp":1761696123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1751991823000931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1751991823000931"],"URL":"https:\/\/doi.org\/10.1016\/j.pcd.2023.04.010","relation":{},"ISSN":["1751-9918"],"issn-type":[{"value":"1751-9918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to insulin glargine 100\u00a0U\/mL treatment in newly-defined subgroups of type 2 diabetes: Post hoc pooled analysis of insulin-na\u00efve participants from nine randomised clinical trials","name":"articletitle","label":"Article Title"},{"value":"Primary Care Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pcd.2023.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Ltd on behalf of Primary Care Diabetes Europe.","name":"copyright","label":"Copyright"}]}}